BrainsWay Unveils Strong Real-World Deep TMS Data in Comorbid PTSD and Depression
TipRanks (Mon, 29-Jun 7:57 AM ET)
Globe Newswire (Mon, 29-Jun 7:30 AM ET)
BrainsWay Reports Favorable Coverage for Accelerated Deep TMS Rises to Over 57 Million Covered Lives
Globe Newswire (Mon, 22-Jun 7:30 AM ET)
Globe Newswire (Tue, 9-Jun 7:30 AM ET)
BrainsWay Announces Minority-Stake Investment in Hopemark Health
Globe Newswire (Mon, 18-May 7:30 AM ET)
BrainsWay Reports First Quarter 2026 Financial Results and Operational Highlights
Globe Newswire (Wed, 13-May 7:30 AM ET)
BrainsWay to Report First Quarter 2026 Financial Results on May 13, 2026
Globe Newswire (Wed, 29-Apr 8:00 AM ET)
Globe Newswire (Wed, 15-Apr 7:30 AM ET)
BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference
Globe Newswire (Mon, 13-Apr 8:00 AM ET)
Market Chameleon (Mon, 12-Jan 3:44 AM ET)
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Brainsway Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol BWAY.
As of June 29, 2026, BWAY stock price climbed to $15.17 with 110,987 million shares trading.
BWAY has a beta of 1.09, meaning it tends to be more sensitive to market movements. BWAY has a correlation of 0.02 to the broad based SPY ETF.
BWAY has a market cap of $608.76 million. This is considered a Small Cap stock.
Last quarter Brainsway Ltd. - American Depositary Shares reported $16 million in Revenue and $.06 earnings per share. This beat revenue expectation by $991,664 and exceeded earnings estimates by $.01.
In the last 3 years, BWAY traded as high as $17.35 and as low as $.50.
The top ETF exchange traded funds that BWAY belongs to (by Net Assets): IZRL, ITEQ, APIE, EHLS, IBRN.
BWAY has outperformed the market in the last year with a price return of +363.2% while the SPY ETF gained +22.3%. However, in the short term, BWAY had mixed performance relative to the market. It has underperformed in the last 3 months, returning +12.5% vs +15.2% return in SPY. But in the last 2 weeks, BWAY shares have fared better than the market returning +3.7% compared to SPY +0.2%.
BWAY support price is $14.02 and resistance is $14.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BWAY shares will trade within this expected range on the day.